Beximco Pharmaceuticals Ltd. — Board/Management Information 2021

Jan 11, 2021

National Storage Mechanism | Additional information

RNS Number : 1557L

Beximco Pharmaceuticals Ltd

11 January 2021

11 January 2021

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

BEXIMCO PHARMACEUTICALS LTD.

Confirmation of Board Changes

Further to the announcement dated 2 December 2020, Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, is pleased to confirm the completion of due diligence enquiries into Ms. Quamrun Naher Ahmed and Ms. Reem H. Shamsuddoha in accordance with the AIM Rules. As a result, Ms. Ahmed and Ms. Shamsuddoha are now confirmed as Non-Executive Directors of the Company.

Additional disclosure information required by Schedule 2(g) of the AIM Rules for Companies

Ms. Quamrun Naher Ahmed

In addition to her appointment to the Board, Ms. Quamrun Naher Ahmed, aged 61, holds or has held the following directorships or partnerships in the past five years:

Current directorships/partnerships: IFIC Bank Limited IFIC Securities Ltd. IFIC Money Transfer (UK) Ltd. Nepal Bangladesh Bank Ltd.	Previous directorships/partnerships: Karmasangsthan Bank

Ms. Ahmed does not have any direct or indirect interest in the issued share capital of the Company but represents IFIC Bank Limited and IFIC Securities Limited.

Ms. Reem H. Shamsuddoha

In addition to her appointment to the Board, Ms. Shamsuddoha, aged 32, holds or has held the following directorships or partnerships in the past five years:

Current directorships/partnerships: Global Voice Holdings Limited Global Voice Telecom Limited Beximco IOC Petroleum & Energy Limited Bangladesh Export Import Co. Ltd	Previous directorships/partnerships: Jete Chao

Ms. Shamsuddoha does not have any direct or indirect interest in the issued share capital of the Company but represents the interests of Absolute Construction and Engineering Limited.

For further information please visit www.beximcopharma.com or enquire to: 

Beximco Pharma
Nazmul Hassan MP, Managing Director Tel: +880 2 58611001, ext.20080
Mohammad Ali Nawaz, Chief Financial Officer Tel: +880 2 58611001, ext.20030
Mohammad Asad Ullah, FCS, Executive Director & Company Secretary Tel: +880 2 58611891, +880 2 58612040, Ext. 10140
SPARK Advisory Partners Limited (Nominated Adviser) Mark Brady / Andrew Emmott Tel: +44 (0)20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker) Vadim Alexandre / Abigail Wayne Tel: +44 (0) 20 3470 0470
FTI Consulting Simon Conway / Victoria Foster Mitchell Tel: +44 (0)20 3727 1000

About Beximco Pharmaceuticals Limited

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCMZGMMVGGGMZM